Literature DB >> 1746050

A hospital survey of hypocalcemia and hypophosphatemia in malignancy.

E D'Erasmo1, M Acca, F S Celi, S Minisola, G Spagna, G Aliberti, G Mazzuoli.   

Abstract

We evaluated the incidence of hypo- versus hypercalcemia and hypo- versus hyperphosphatemia in a survey of 158 patients with malignancy; 55/158 had bone metastases. When serum calcium levels were corrected for albuminemia, the incidence of hypo- and hypercalcemia was respectively 10.8% and 10.1%. Hypophosphatemia was found in 29.7% patients, hyperphosphatemia in 2.5%. The incidence was slightly different in presence of bone metastases. Hypocalcemia and hypophosphatemia prevailed in osteoblastic metastases and hypercalcemia in osteolytic metastases. The incidence of hypocalcemia and hypophosphatemia in malignancy was therefore surprisingly high, even apart from the presence of bone metastases. Both hypo- and hypercalcemia were associated with elevated serum alkaline phosphatase levels. Moreover, a calcium-phosphorus product reduction was observed in osteoblastic metastases, suggesting a condition of secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1746050     DOI: 10.1177/030089169107700403

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  Hypocalcemia in cancer patients: An exploratory study.

Authors:  José António Ferraz Gonçalves; Telma Costa; Joana Rema; Cristina Pinto; Miguel Magalhães; Ana Esperança; Luciana Sousa
Journal:  Porto Biomed J       Date:  2019-07-08

2.  Outcome of Critically Ill Patients with Testicular Cancer.

Authors:  Silvio A Ñamendys-Silva; Mireya Barragán-Dessavre; Andoreni R Bautista-Ocampo; Francisco J García-Guillén; Bertha M Córdova-Sánchez; Edgar Constantino-Hérnandez; Paulina Correa-García; Octavio González-Chon; Angel Herrera-Gómez
Journal:  Biomed Res Int       Date:  2017-10-26       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.